Back to News
Market Impact: 0.4
RVTY Q3 Earnings Beat Estimates on Life Sciences Strength, '26 View Up
Source: zacks.com
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Revvity beat Q3 2026 earnings and revenue estimates, supported by Life Sciences growth and margin expansion. The company raised its annual outlook; the article provides no specific financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
RVTY0.80
More News
- Revvity stock rises 5% on strong earnings beat and raised guidance
- Stocks making the biggest moves midday: Apple, Palantir, Nvidia, Coinbase, Bloom Energy & more
- Stocks making the biggest moves premarket: Pfizer, Apple, Palantir, Zebra Technologies & more
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition